Skip to main content
. 2022 Nov 14;2022(11):CD001021. doi: 10.1002/14651858.CD001021.pub4

5.2. Analysis.

5.2

Comparison 5: Inhaled aztreonam lysine (AZLI) versus tobramycin for inhalation solution (TIS), Outcome 2: FEV1 % predicted ‐ mean actual change from baseline